The first poly(2-ethyl-2-oxazoline) (POZTM) polymer therapeutic is entering Phase Ib in patients with Parkinson’s disease (PD), and the design, pre-clinical and clinical results of this candidate drug will be reviewed during this lecture. SER-214 is a twenty kDa ten pendent polymer with ten rotigotine molecules attached employing copper-catalyzed “click chemistry”. In patients that lack sufficient dopamine signaling, continuous drug delivery of a potent dopaminergic agent such as rotigotine provides continuous dopaminergic tone – a long-sought clinical strategy that obviates the phasic "peak and trough" profiles of oral agents. The second molecule in addressing the unmet medical need in PD has entered pre-clinical studies. SER-240 is a POZ conjugate of apomorphine, one of the most potent dopamine agonists known. This product candidate is being developed for treatment of advanced PD patients who have significant periods of “off” time during daily awake periods. In this lecture I will also provide an update on the pipeline at Serina. SER-227 is a one-time injection of POZ-buprenorphine that may be delivered in the recovery room following surgery. SER-227 is designed to provide immediate (within 1-2 hours) and prolonged (3-4 days) continuous drug delivery of buprenorphine - an analgesic that will also address the opioid epidemic in the US. Finally, I will provide an update on our POZ-cannabinoid programs with special emphasis on SER-228 – a POZ conjugate of cannabidiol (CBD) that provides continuous delivery of CBD. SER-228 wil initially be developed for refractory epilepsy, but may also be effective in a myriad of other clinical indications.

POZTM – poly(2-oxazoline) update on next generation in polymer therapeutics

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.